Cypherpunk Technologies, ordinary share
CYPH, US52187K2006
CBONDSウォッチリストで投資を発見、保存、追跡
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
最も包括的なデータベースを探索
1 000 000
債券
100 000
株
175 910
ETF&投資信託
100 000
インデックス
最も効率的な方法でポートフォリオを追跡
|
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and
...
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
|